2nd Edition of World Nanotechnology Conference

April 19-21, 2021 | Virtual Event

Scopus Indexed Conference
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Whatsapp: +1 (540) 709-1879
Email: worldnano@magnus-group.org
April 19-21, 2021 | Virtual Event

Chin-Tarng Lin

Speaker for Nanotechnology Conferences  2020
Chin-Tarng Lin
National Taiwan University Hospital, Taiwan
Title : Preclinical evaluation of the efficacy of peptide targeting chemotherapy for cancers


The purpose of this abstract was to assess the efficacy of peptide targeted chemotherapy for pancreatic carcinoma. Previously we have constructed four peptides that bind specifically to cancer cell lines, which were derived from three different carcinoma cell lines and their vascular endothelia: L-peptide: (L-P, anti-cancer cell membrane), RLLDTNRPLLPY; SP-94-P (anti-hepato-pancreatic cancer cell membrane), SFSHHTPILP; PC5-52-peptide (anti-tumor endothelia), SVSVGMKPSPRP; and control peptide, RLLDTNRGGGGG. These peptides were linked to pegylated liposomal iron oxide nanoparticles to identify the targeted tumor cells and vascular endothelia using MRI analysis, and were also linked to dextran coated liposomal doxorubicin (L-D) for treatment of non-obese diabetic, severe combined immunodeficiency (NOD-SCID) mice bearing pancreatic cancer cell (PANC-1) xenografts. Our results demonstrated that the tumor intensity of MRI is clearly decreased after SP-94-P-iron oxide was applied, and that in combination of application of L-P linked L-D (L-P-L-D) plus SP-94-P linked L-D (SP-94-P-L-D) and PC5-52-P linked L-D (PC5-52-P-L-D), they could inhibit pancreatic tumor growth with very mild adverse events. The use of the control peptide linked L-D also led to a decrease of the xenograft size, but also induced marked apoptotic change of their visceral organs. It is concluded that the combination of L-P-L-D, SP-94-P-L-D and PC5-52-P-L-D to treat pancreatic cancer xenograft in NOD SCID mice can clearly inhibit pancreatic cancer growth with minimal adverse events.

Audience take away:

  • Nasopharyngeal carcinoma

  • Breast cancer

  • L-peptide

  • Peptide histochemistry

  • Peptide-targeted MRI and chemotherapy


Dr. Chin-Tarng Lin, D.D.S., Ph.D., has devoted several decades to perform molecular pathological cancer research. He was a pathology professor and is an Emeritus professor right now at the College of Medicine, National Taiwan University. He has published more than 92 papers and obtained 12 patents, and has been invited to give the scientific seminar over 75 times. He has presented 191 abstracts to attend the world wide biomedical science meetings. His research interests include the development of immunohistochemical localization of protein, mRNA and DNA molecules at the light and electron microscopic levels and peptide histochemistry to identify the peptide targeted binding protein. He has established 10 nasopharyngeal carcinoma cell lines (NPC-TW01to10) and five endometrioid cancer cell lines (OV-TW59-P0 to-P4) in his laboratory. His major interests are to investigate the molecular pathogenesis of NPC with or without Epstein-Barr virus infection and of ovarian cancer. He and his colleague have identified 3 specific peptides to localize their targeted proteins, to identify the cancer xenograft by MRI and to perform peptide-targeted chemotherapy for different cancers with minimal adverse event.